Clinical Trials

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01523977 2024-07-18

CRAD001NUS175T

LymphoidOther hematologic neoplasm

22 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00387400 2023-08-04

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

32 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT03328104 2023-07-21

ENCERT

LymphoidOther hematologic neoplasm

8 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01430572 2023-06-06

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

62 enrolled

Other solid neoplasm

Advanced Cancers

NCT02106507 2023-05-26

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

9 enrolled

Prostatic Neoplasms

NCT03355794 2023-01-13

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

19 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

BreastGastrointestinalGenitourinaryThoracic

298 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01154439 2022-10-26

AML1208

Other hematologic neoplasm

11 enrolled

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT00981162 2022-09-13

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

12 enrolled

Pancreatic Neoplasms

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

BreastGenitourinaryOther solid neoplasmThoracic

210 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

27 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01154335 2022-05-03

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

18 enrolled 9 charts

Colorectal Neoplasms

NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

EndocrineGenitourinaryNET

44 enrolled 9 charts

Kidney Neoplasms, Neuroendocrine Tumors

NCT03387020 2021-08-27

Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

22 enrolled 16 charts

CNS

Familial ependymoma, Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma, Rhabdoid Tumor

NCT02125084 2021-05-04

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

38 enrolled

Prostatic Neoplasms

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

132 enrolled

Breast Neoplasms

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01624766 2021-02-25

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

57 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01197170 2021-01-22

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

277 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT00426530 2020-12-21

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

50 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00434174 2020-12-21

Safety of Everolimus and Pemetrexed in Lung Cancer Patients

48 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00456833 2020-12-21

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

248 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00466466 2020-12-21

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

20 enrolled

Small Cell Lung Carcinoma

NCT00622258 2020-12-21

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

13 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT01152801 2020-12-21

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

64 enrolled

Carcinoma, Renal Cell

NCT01263353 2020-12-21

COOPERATE-1

36 enrolled

Endocrine

Carcinoid Tumor

NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

46 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT01854606 2020-12-19

COEB071X2103

31 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02152943 2020-12-19

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

37 enrolled

Breast Neoplasms

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

79 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT02138929 2020-06-11

LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma

25 enrolled

Esophageal Neoplasms, Neoplasm Metastasis

NCT01596140 2020-06-04

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

27 enrolled

Other solid neoplasm

Advanced Cancer

NCT01049620 2020-01-07

RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX

40 enrolled

Advanced Gastric Cancer

NCT01184326 2019-10-02

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

23 enrolled 16 charts

Kidney Neoplasms

NCT01061788 2019-08-28

RAP

43 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01281514 2019-07-11

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

21 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01590199 2019-04-16

MACS2002

18 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02454478 2019-03-19

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

7 enrolled 17 charts

Carcinoma, Carcinoma, Renal Cell

NCT01490749 2019-03-15

Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

17 enrolled

Esophageal Neoplasms

NCT02240719 2019-01-04

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer